

Synthesis and antibacterial activity of some novel spiro [3*H*-indole-3,5'-[1,3,4]oxadiazolo[3,2-*c*]thiazole]-2(1*H*)-ones and [1,3,4]oxadiazino[6,5-*b*]indoles containing 1,8-naphthyridine moiety

K Mogilaiah*, P Raghotham Reddy & R Babu Rao

Department of Chemistry, University Arts & Science College, Kakatiya University, Subedari, Warangal 506 001, India

Received 19 April 1999; accepted 2 September 1999

Interaction of 2-phenyl-1,8-naphthyridine-3-carboxylic acid hydrazide **1** with different isatins **2** gives the corresponding isatin- β -(2-phenyl-1,8-naphthyridine-3-carbonylhydrazones) **3**. Cyclocondensation of **3** with mercaptoacetic acid in DMF in the presence of anhyd. ZnCl₂ affords 3'-(2-phenyl-1,8-naphthyridine-3-carbonylamino)spiro[3*H*-indole-3,2'-thiazolidine]-2,4' (1*H*)-diones **4**, which on treatment with conc. H₂SO₄ undergo cyclodehydration to furnish the desired 2'-(2-phenyl-1,8-naphthyridin-3-yl) spiro[3*H*-indole-3,5'-[1,3,4]oxadiazolo[3,2-*c*]thiazole]-2(1*H*)-ones **5**. On the other hand, the hydrazones **3** on treatment with conc. H₂SO₄ leads to the formation of 2-(2-phenyl-1,8-naphthyridin-3-yl)-[1,3,4]oxadiazino[6,5-*b*]indoles **6**. The structures of the compounds **3-6** have been established on the basis of their elemental analyses and spectral (IR, ¹H NMR and mass) data. The compounds **5** and **6** have been screened for their antibacterial activity.

Literature survey reveals that both 1,3,4-oxadiazoles^{1,2} and thiazoles^{3,4} are well known for their varied pharmacological and microbiological activities. Certain 1,8-naphthyridine derivatives are reported to be useful antibacterial^{5,6} diuretic⁷, antimalarial⁸, anti-inflammatory⁹ and antitumor¹⁰ agents. The indole¹¹⁻¹³ and 1,3,4-oxadiazine¹⁴ classes of heterocycles are of current interest due to their broad spectrum biological activity. Furthermore, in recent years chemistry on nitrogen bridged heterocycles has emerged as a frontier area of research in synthetic organic chemistry. Encouraged by these reports and in continuation of our interest in the chemistry of 1,8-naphthyridines¹⁵⁻²¹, we report herein, the synthesis of a novel bridgehead nitrogen heterocyclic system containing a spiro-linkage, viz., spiro[3*H*-indole-3,5'-[1,3,4]oxadiazolo-[3,2-*c*]oxadiazino[6,5-*b*]indoles containing 1,8-naphthyridine moiety. These compounds have been synthesized following the reaction sequence shown in **Scheme I**.

The starting compound, 2-phenyl-1,8-naphthyridine-3-carboxylic acid hydrazide **1** required for the preparation of the target compounds, was obtained by hydrazinolysis of ethyl 2-phenyl-1,8-naphthyridine-3-carboxylate¹⁹, which in turn was prepared by the condensation of 2-aminonicotinaldehyde with ethyl benzoyl acetate in boiling methanol containing a catalytic amount of piperidine¹⁹. Compound **1** on reaction with different isatins **2** in methanol

containing a catalytic amount of gl. acetic acid furnished the corresponding isatin- β -(2-phenyl-1,8-naphthyridine-3-carbonylhydrazones) **3** in very good yields. The hydrazones **3** on cyclocondensation with mercaptoacetic acid in refluxing DMF in the presence of anhyd. ZnCl₂ afforded 3'-(2-phenyl-1,8-naphthyridine-3-carbonylamino)-spiro[3*H*-indole-3,2'-thiazolidine]-2,4'(1*H*)-diones **4**, which on cyclodehydration with conc. H₂SO₄ yielded 2'-(2-phenyl-1,8-naphthyridin-3-yl)spiro[3*H*-indole-3,5'-[1,3,4]oxadiazolo[3,2-*c*]thiazole]-2-(1*H*)-ones **5**.

Further, the hydrazones **3** on treatment with conc. H₂SO₄ at room temperature underwent cyclodehydration to afford 2-(2-phenyl-1,8-naphthyridin-3-yl)-[1,3,4]oxadiazino[6,5-*b*]indoles **6** (**Scheme I**, **Table I**).

The structural assignments to compounds **3-6** were based on their elemental analyses and spectral (IR, ¹H NMR and mass) data.


Antibacterial activity

The antibacterial activity of the compounds **5a-g** and **6a-g** was determined by filter paper disc method²² against the following bacteria *Escherichia coli*, *Pseudomonas aeruginosa*, *Bacillus subtilis* and *Bacillus mycoides* at 400 and 600 μ g/disc concentrations using streptomycin as a standard drug at same concentration for comparison. The results are presented in **Table II**. The antibacterial activity data indicate that all the compounds are moderately to

highly active to the test bacteria at 600 $\mu\text{g}/\text{disc}$ concentration. The activity of the compound depends upon the nature and position of the substituent at the indole moiety. Compounds **5b**, **5e**, **5f** and **6e** displayed promising antibacterial activity. Introduction of methoxyl group at indole moiety diminishes the activity of the compounds. Compound **5e** showed remarkable and comparable activity with that of standard drug streptomycin at the same concentration.

Experimental Section

General. Melting points were taken in open capillaries on a Cintex melting point apparatus and are uncorrected. Purity of the compounds were checked by TLC. IR spectra were recorded in KBr on a Perkin-Elmer 337 spectrophotometer (ν_{max} in cm^{-1}), ^1H NMR spectra on a Varian Gemini 200 MHz spectrometer using TMS as internal standard (chemical shifts in δ , ppm) and mass spectra on a VG micromass 70 70 H instrument at 70 eV.



Scheme I

Table I— Characterization data of compounds 3 - 6

Compd	R	m.p. °C	Yield (%)	Mol. formula	Found (%) (Calcd)		
					C	H	N
3a	H	252	78	C ₂₃ H ₁₅ N ₅ O ₂	70.38 (70.2)	3.86 (3.82)	17.74 (17.81)
3b	5-CH ₃	230	90	C ₂₄ H ₁₇ N ₅ O ₂	70.74 (70.76)	4.21 (4.18)	17.32 (17.20)
3c	7-CH ₃	216	86	C ₂₄ H ₁₇ N ₅ O ₂	70.93 (70.76)	4.22 (4.18)	17.31 (17.20)
3d	3-OCH ₃	238	83	C ₂₄ H ₁₇ N ₅ O ₃	68.24 (68.09)	4.08 (4.02)	16.48 (16.55)
3e	5-Cl	226	88	C ₂₃ H ₁₄ N ₅ O ₂ Cl	64.82 (64.64)	3.21 (3.28)	16.46 (16.39)
3f	7-Cl	242	84	C ₂₃ H ₁₄ N ₅ O ₂ Cl	64.80 (64.64)	3.23 (3.28)	16.45 (16.39)
3g	5-Br	194	80	C ₂₃ H ₁₄ N ₅ O ₂ Br	8.33 (58.47)	2.88 (2.97)	14.94 (14.83)
4a	H	300	70	C ₂₅ H ₁₇ N ₅ O ₃ S	64.40 (64.24)	3.68 (3.64)	14.91 (14.99)
4b	5-CH ₃	>300	80	C ₂₆ H ₁₉ N ₅ O ₃ S	64.72 (64.86)	3.91 (3.95)	14.63 (14.55)
4c	7-CH ₃	>300	75	C ₂₆ H ₁₉ N ₅ O ₃ S	64.70 (64.86)	3.90 (3.95)	14.65 (14.55)
4d	5-OCH ₃	>300	73	C ₂₆ H ₁₉ N ₅ O ₄ S	62.95 (62.78)	3.76 (3.82)	14.14 (14.08)
4e	5-Cl	>300	78	C ₂₅ H ₁₆ N ₅ O ₃ SCl	59.72 (59.88)	3.13 (3.19)	13.83 (13.97)
4f	7-Cl	>300	74	C ₂₅ H ₁₆ N ₅ O ₃ SCl	59.71 (59.85)	3.15 (3.19)	13.81 (13.97)
4g	5-Br	>300	72	C ₂₅ H ₁₆ N ₅ O ₃ SBr	54.80 (54.95)	2.86 (2.93)	12.91 (12.82)
5a	H	>300	50	C ₂₅ H ₁₅ N ₅ O ₂ S	66.75 (66.82)	3.42 (3.34)	15.70 (15.59)
5b	5-CH ₃	>300	65	C ₂₆ H ₁₇ N ₅ O ₂ S	67.53 (67.39)	3.62 (3.67)	15.23 (15.12)
5c	7-CH ₃	>300	60	C ₂₆ H ₁₇ N ₅ O ₂ S	67.55 (67.39)	3.60 (3.67)	15.25 (15.12)
5d	5-OCH ₃	>300	58	C ₂₆ H ₁₇ N ₅ O ₃ S	65.32 (65.14)	3.63 (3.55)	14.72 (14.61)
5e	5-Cl	>300	63	C ₂₅ H ₁₄ N ₅ O ₂ SCl	62.32 (62.11)	2.75 (2.90)	14.55 (14.49)
5f	7-Cl	>300	61	C ₂₅ H ₁₄ N ₅ O ₂ SCl	62.34 (62.11)	2.72 (2.90)	14.56 (14.49)
5g	5-Br	>300	56	C ₂₅ H ₁₄ N ₅ O ₂ SBr	56.65 (56.82)	2.61 (2.65)	13.40 (13.26)
6a	H	258(d)	55	C ₂₃ H ₁₃ N ₅ O	73.78 (73.60)	3.41 (3.47)	18.79 (18.67)
6b	6-CH ₃	274	70	C ₂₄ H ₁₅ N ₅ O	74.23 (74.04)	3.82 (3.86)	17.80 (17.99)
6c	8-CH ₃	>300	66	C ₂₄ H ₁₅ N ₅ O	74.22 (74.04)	3.80 (3.86)	17.82 (17.99)
6d	6-OCH ₃	>300	64	C ₂₄ H ₁₅ N ₅ O ₂	71.24 (71.11)	3.79 (3.70)	17.37 (17.28)
6e	6-Cl	262	68	C ₂₃ H ₁₂ N ₅ OCl	67.60 (67.48)	2.99 (2.93)	17.26 (17.11)
6f	8-Cl	283	63	C ₂₃ H ₁₂ N ₅ OCl	67.62 (67.48)	2.97 (2.93)	17.28 (17.11)
6g	8-Br	247	65	C ₂₃ H ₁₂ N ₅ OBr	60.61 (60.79)	2.61 (2.64)	15.54 (15.42)

Table II—Antibacterial activity results of the compounds **5** and **6**

Compd	Inhibition zone (in mm) against							
	<i>E. coli</i> at		<i>P. aeruginosa</i> at		<i>B. subtilis</i> at		<i>B. mycoides</i> at	
	400 µg/disc.	600 µg/disc.	400 µg/disc.	600 µg/disc.	400 µg/disc.	600 µg/disc.	400 µg/disc.	600 µg/disc.
5a	4.5	5.5	3.5	4.5	3.0	4.0	2.5	3.5
5b	7.5	8.5	6.5	8.0	5.5	7.0	4.5	5.5
5c	6.5	8.0	6.0	7.5	5.0	6.5	4.0	5.0
5d	3.5	5.0	2.5	3.5	2.0	3.5	2.5	3.5
5e	11.5	13.5	10.5	12.0	8.5	10.0	7.5	8.5
5f	9.5	10.5	8.5	10.0	7.0	9.0	7.0	8.0
5g	6.0	7.5	5.5	6.5	4.5	5.5	4.0	5.0
6a	3.5	4.5	2.5	3.5	2.0	3.0	1.5	2.5
6b	6.5	8.0	5.0	6.0	4.0	5.5	3.0	4.5
6c	5.5	6.5	4.0	5.5	3.5	4.0	2.5	3.5
6d	3.0	4.0	2.5	3.5	2.0	3.5	3.0	4.0
6e	10.0	11.5	8.5	10.0	7.0	8.5	6.5	8.0
6f	7.0	8.5	6.0	7.0	5.0	6.5	4.0	5.5
6g	5.0	6.5	4.5	5.5	3.0	4.5	2.5	3.5
Streptomycin	13.0	15.0	15.0	17.0	10.0	12.0	9.0	11.0

Isatin-β-(2-phenyl-1,8-naphthyridine-3-carbonylhydrazone) 3a. A mixture of **1** (0.01 mole) and **2** (R = H, 0.01 mole) in methanol (30 mL) in the presence of a catalytic amount of gl. acetic acid was heated under reflux for 30 min. The solid that separated on cooling was filtered, washed with cold methanol and recrystallized from methanol to give **3a**, yield 78%, m.p. 252°C; IR (KBr) : 3207 (NH), 1732 (indole C=O), 1665 (CONH), 1607 cm⁻¹ (C=N); ¹H NMR (DMSO-*d*₆) : δ 8.3 (m, 1H, C₄-H), 8.7 (m, 1H, C₅-H), 7.8 (m, 1H, C₆-H), 9.2 (m, 1H, C₇-H), 6.8-7.5 (m, 9H, Ar-H), 10.6 (s, 1H, CONH), 11.05 (s, 1H, indole NH); MS : m/z 393 (M⁺, 5.6%), 365 (8), 248 (14), 233 (100), 206 (30), 205 (44), 178 (7), 102 (23.3), 91 (43.5), 75 (13.3).

Other compounds in the series were prepared similarly and are listed in **Table I**.

3-(2-Phenyl-1,8-naphthyridine-3-carbonylamino)-spiro[3H-indole-3,2'-thiazolidine]-2,4'(1H)-dione 4a. A mixture of **3a** (0.01 mole) and mercaptoacetic acid (0.01 mole) in DMF (30 mL) containing a pinch of anhyd. ZnCl₂ was heated under reflux for 6 hr. The reaction mixture was cooled and poured onto crushed ice. The solid thus obtained was filtered, washed with water and recrystallized from DMF to afford **4a**, yield 70%, m.p. 300°C; IR (KBr) : 3245 (NH), 1740 (thiazolidinone C=O), 1695 (indole C=O, and CONH), 1600 cm⁻¹ (C=N); MS : m/z 467 (M⁺, 6.4%), 425 (12.5), 248 (20), 233 (100), 219 (7.5%), 205 (68), 178 (32), 177 (16), 102 (52), 75 (18).

Other compounds in the series were prepared similarly and are listed in **Table I**.

2'-(2-Phenyl-1,8-naphthyridin-3-yl)spiro[3H-indole-3,5'-[1,3,4]oxadiazolo [3,2-c]thiazole]-2(1H)-one 5a. Compound **4a** (0.01 mole) was added slowly to conc. H₂SO₄ (10 mL) in the cold. The reaction mixture was kept for 6 hr at room temperature, poured onto crushed ice and neutralized with ammonia solution. The precipitate thus obtained was filtered, washed with water and recrystallized from DMF to furnish **5a**, yield 50%, m.p. >300°C; IR (KBr) : 3250 (NH) 1723 (C=O), 1605 (C=N), 1220 cm⁻¹ (C-O-C); ¹H NMR (DMSO-*d*₆) : δ 8.2 (m, 1H, C₄-H), 8.6 (m, 1H, C₅-H), 7.85 (m, 1H, C₆-H), 9.1 (m, 1H, C₇-H), 6.9-7.6 (m, 10H, 9 ArH and C=CH-S), 11.2 (s, 1H, indole NH); MS : m/z 449 (M⁺, 18%), 247 (29.6), 231 (70.4), 218 (37), 205 (100), 178 (12), 163 (8.5), 102 (25.9), 75 (18.5).

Other compounds in the series were prepared similarly and are listed in **Table I**.

2-(2-Phenyl-1,8-naphthyridin-3-yl)-[1,3,4]oxadiazino[6,5-*b*]indole 6a. Hydrazone **3a** (0.01 mole) was dissolved, with cooling, in conc. H₂SO₄ (10 mL). The reaction mixture stirred well, kept for 5 hr at room temperature, poured onto crushed ice and neutralized with ammonia solution. The resulting solid was filtered, washed thoroughly with water and recrystallized from methanol to obtain **6a**, yield 55%, m.p. 258°C (d); IR (KBr) : 1606 (C=N), 1216 cm⁻¹ (C-O-C); ¹H NMR (DMSO-*d*₆) : δ 8.2 (m, 1H, C₄-H), 8.8 (m, 1H, C₅-H), 7.8 (m, 1H, C₆-H), 9.15 (m, 1H, C₇-H), 6.7 - 7.5 (m, 9H, Ar-H); MS : m/z 375 (M⁺, 12%), 231 (100), 205 (18), 178 (9.5), 170 (15.6), 142 (26), 131 (43).

Other compounds in the series were prepared similarly and are listed in **Table I**.

Acknowledgement

The authors are grateful to the Director, IICT, Hyderabad for ^1H NMR and mass spectral data of the compounds. They are also thankful to the Principal, University Arts & Science College, Kakatiya University, Warangal for providing necessary facilities.

References

- 1 Sengupta A K, Srivastava N & Gupta A A, *Indian J Chem*, 21B, **1982**, 793.
- 2 Dutta M M, Goswami B N & Katakya J C S, *J Indian Chem Soc*, 64, **1987**, 195.
- 3 Brown K, Cater D P, Cavalla J F, Freen D & Newberry R A, *J Med Chem*, 17, **1974**, 1177.
- 4 Mane R A & Ingle D B, *Indian J Chem*, 22B, **1983**, 81.
- 5 Egawa H, Miyamoto T, Minamida A, Nishimura Y, Okada H, Uno H & Motosumoto T, *J Med Chem*, 27, **1984**, 1543.
- 6 Cooper C S, Klock P L, Chu D T W, Hardy D J, Swanson R N & Pattner J J, *J Med Chem*, 35, **1992**, 1392.
- 7 Gorecki D K J & Hawes E M, *J Med Chem*, 20, **1977**, 124.
- 8 Balin G B & Tan W L, *Aust J Chem*, 37, **1984**, 1065.
- 9 Kuroda T, Suzuki F, Tamura T, Ohmori K & Hosoe H, *J Med Chem*, 35, **1992**, 1130.
- 10 Chen K, Kuo S, Hsieh M & Anthoner K, *J Med Chem*, 40, **1997**, 3049.
- 11 Joshi K C, Jain R, Chand P & Garg S, *J Indian Chem Soc*, 60, **1983**, 760.
- 12 Hiremath S P, Ullagaddi A & Purohit M G, *Indian J Chem*, 27B, **1988**, 1102.
- 13 Husain M I, Jamali M R & Srivasatava R C, *Indian J Chem*, 28B, **1989**, 532.
- 14 Trepanier D L, John N E & Sprancmanis V, *J Med Chem*, 9, **1966**, 753.
- 15 Mogilalah K, Reddy K R, Rao G R & Sreenivasulu B, *Colln Czech Chem Commun*, 53, **1988**, 1539.
- 16 Reddy K R, Mogilalah K, Swamy B & Sreenivasulu B, *Acta Chim Hung*, 127, **1990**, 45.
- 17 Rao J S, Sreenivasulu B & Mogilalah K, *Indian J Chem*, 34B, **1995**, 734.
- 18 Rani H S, Mogilalah K & Sreenivasulu B, *Indian J Chem*, 35B, **1996**, 106.
- 19 Rao G R, Mogilalah K & Sreenivasulu B, *Indian J Chem*, 35B, **1996**, 339.
- 20 Mogilalah K & Rao R B, *Indian J Chem*, 37B, **1998**, 139.
- 21 Mogilalah K & Rao R B, *Indian J Chem*, 37B, **1998**, 894.
- 22 Vincent J C & Vincent H W, *Proc Soc Exptl Biol Med*, 55, **1944**, 162.